Ono Pharmaceutical announced collaboration agreement with Adimab to discover and develop innovative antibody drugs in the oncology field.
As part of the collaboration agreement, Ono Pharmaceutical will hold the option to secure exclusive global rights for the development, manufacturing, and commercialisation of any antibody candidates resulting from this partnership.
Under this agreement, Adimab will leverage its expertise to identify novel therapeutic antibodies against specific targets chosen by Ono. These antibodies will be designed to combat various aspects of cancer.
This collaboration agreement will focus on the bispecific antibodies, which have the potential to enhance the effectiveness of cancer treatments by targeting two different molecules or pathways simultaneously.
The collaboration between Ono and Adimab combines Adimab's advanced multi-specific antibody engineering technologies with Ono's commitment to addressing the needs of cancer patients. This collaboration is expected to expedite the development of targeted antibody products for individuals battling cancer, with the ultimate goal of bringing these innovative treatments to patients as swiftly as possible.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!